Journal Information
ISSN / EISSN : 00987484 / 15383598
Current Publisher: American Medical Association (AMA) (10.1001)
Total articles ≅ 248,364
Google Scholar h5-index: 209
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

Jennifer Abbasi
JAMA: The Journal of the American Medical Association; doi:10.1001/jama.2019.12232

Jennifer Abbasi
JAMA: The Journal of the American Medical Association; doi:10.1001/jama.2019.10432

Susan Frances Martinello
JAMA: The Journal of the American Medical Association, Volume 322, pp 698-698; doi:10.1001/jama.2019.5687

Feyza Sancar
JAMA: The Journal of the American Medical Association, Volume 322, pp 604-604; doi:10.1001/jama.2019.11515

Bridget Kuehn
JAMA: The Journal of the American Medical Association, Volume 322, pp 603-603; doi:10.1001/jama.2019.11801

Bridget Kuehn
JAMA: The Journal of the American Medical Association, Volume 322, pp 603-603; doi:10.1001/jama.2019.11802

Bradley A. Gross, Brian T. Jankowitz, Robert M. Friedlander
JAMA: The Journal of the American Medical Association, Volume 322, pp 694-695; doi:10.1001/jama.2019.8658

Matthew K. Hensley
JAMA: The Journal of the American Medical Association, Volume 322, pp 613-614; doi:10.1001/jama.2019.11287

JAMA: The Journal of the American Medical Association, Volume 322, pp 699-699; doi:10.1001/jama.2018.15473

Heidi D. Nelson, Miranda Pappas, Amy Cantor, Elizabeth Haney, Rebecca Holmes
JAMA: The Journal of the American Medical Association, Volume 322, pp 666-685; doi:10.1001/jama.2019.8430

Abstract:Pathogenic mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 are associated with increased risks for breast, ovarian, fallopian tube, and peritoneal cancer in women, breast cancer in men, and, to a lesser degree, pancreatic and early-onset prostate cancer1-6; BRCA2 is also associated with melanoma.3,4BRCA1/2 mutations cluster in families, exhibiting an autosomal dominant pattern of transmission in either the maternal or paternal lineage. Penetrance, the probability of developing cancer in BRCA1/2 mutation carriers, is variable, and many carriers never develop cancer.